About lixte biotechnology holdings inc - LIXT
Lixte Biotechnology Holdings, Inc. is a clinical-stage biopharmaceutical company, which engages in the business of developing a drug class called protein phosphatase 2A inhibitors. The firm is also involved in utilizing biomarker technology to identify enzyme targets associated with serious common diseases and then designing novel compounds to attack those targets. The company was founded by John S. Kovach and Robert B. Royds on May 24, 2005 and is headquartered in Boca Raton, FL.
LIXT At a Glance
Lixte Biotechnology Holdings, Inc.
433 Plaza Real
Boca Raton, Florida 33432
| Phone | 1-631-830-7092 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -3,585,965.00 | |
| Sector | Health Technology | Employees | 2 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
LIXT Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -1.967 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | N/A |
LIXT Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,792,982.50 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
LIXT Liquidity
| Current Ratio | 3.599 |
| Quick Ratio | 3.599 |
| Cash Ratio | 3.264 |
LIXT Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -131.496 |
| Return on Equity | -148.734 |
| Return on Total Capital | -433.496 |
| Return on Invested Capital | -148.734 |
LIXT Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | N/A |
| Total Debt to Total Assets | N/A |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |